Merck
  • Home
  • Search Results
  • The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.

The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.

Renal failure (2014-07-01)
Akira Matsuo, Akio Iida, Minako Tanimoto, Mutsuyoshi Matsushita, Ken-ichi Miyamoto
ABSTRACT

Hyperphosphatemia is a risk factor for arterial calcification contributing to the high-cardiovascular mortality in patients with chronic kidney disease (CKD). Ferric citrate hydrate (JTT-751) is being developed as a treatment for hyperphosphatemia with chronic renal failure and has shown a serum phosphorus-lowering effect in CKD patients. In this study, we evaluated the combination effect of JTT-751 with the phosphorus absorption-reducing effect of calcium carbonate and compared phosphorus absorption-reducing efficacy between three phosphate binders including JTT-751. Normal rats were fed a diet containing either 1% calcium carbonate, 1% JTT-751 or 1% JTT-751 with 1% calcium carbonate, for 7 days. Both 1% calcium carbonate and 1% JTT-751 alone reduced urinary phosphorus excretion, and the combined treatment reduced it more than each single-treatment, without clearly influencing calcium or iron-metabolism. Next, normal rats were fed a diet containing either 0.3, 1 and 3% lanthanum carbonate or 2.3% JTT-751, for 7 days. Either 3% lanthanum carbonate or 2.3% JTT-751 reduced urinary phosphorus excretion. Finally, we compared the reduced amount of urinary phosphorus excretion per dose of compound, of which JTT-751 is comparable to that of calcium carbonate and is greater than that of the lanthanum carbonate. In conclusion, JTT-751 showed an additive effect on the phosphorus absorption-reducing effect of calcium carbonate without influencing calcium- and iron-metabolism, and had a phosphorus absorption-reducing efficacy comparable to or greater than other existing phosphate binders.

MATERIALS
Product Number
Brand
Product Description

USP
Calcium Carbonate (AS), United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Creatinine, anhydrous, ≥98%
Sigma-Aldrich
Calcium carbonate, ≥99.995% trace metals basis
Sigma-Aldrich
Calcium carbonate, powder, ≤50 μm particle size, 98%
Sigma-Aldrich
Calcium carbonate, 99.999% trace metals basis
Supelco
Calcium carbonate, certified reference material for titrimetry, certified by BAM, ≥99.5%
Sigma-Aldrich
Calcium carbonate, BioUltra, precipitated, ≥99.0% (KT)
Sigma-Aldrich
Calcium carbonate, tested according to Ph. Eur.
Sigma-Aldrich
Calcium carbonate, BioXtra, ≥99.0%
Sigma-Aldrich
Calcium carbonate, BioReagent, suitable for insect cell culture, ≥99.0%
Sigma-Aldrich
Calcium carbonate, ACS reagent, chelometric standard, 99.95-100.05% dry basis
Supelco
Calcium carbonate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Calcium carbonate, Vetec, reagent grade, 99%
Supelco
Creatinine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Calcium carbonate, ACS reagent, ≥99.0%, powder
Sigma-Aldrich
Calcium carbonate, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Sigma-Aldrich
Calcium carbonate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E170, precipitated, 98.5-100.5% (based on anhydrous substance)
Sigma-Aldrich
Calcium carbonate, ReagentPlus®